Screener
Kiniksa Pharmaceuticals International, plc KNSA EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed July 28, 2026.
- Filed
- Jul 28, 2026, 4:17 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-087545
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Provision for income taxes | (5,713) | (5,045) | (15,802) | (12,071) |
| Net income | $25,432 | $17,832 | $48,024 | $26,371 |
| Net income per share attributable to ordinary shareholders—basic | $0.33 | $0.24 | $0.62 | $0.36 |
| Net income per share attributable to ordinary shareholders—diluted | $0.30 | $0.23 | $0.58 | $0.34 |
| Weighted average ordinary shares outstanding—basic | 77,577,675 | 73,438,530 | 77,050,036 | 73,041,920 |
| Weighted average ordinary shares outstanding—diluted | 83,398,051 | 77,942,082 | 82,902,904 | 76,984,393 |
| Comprehensive income | ||||
| Net income | $25,432 | $17,832 | $48,024 | $26,371 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Kiniksa Pharmaceuticals International, plc's EPS (diluted)?
- Kiniksa Pharmaceuticals International, plc (KNSA) reported EPS (diluted) of $0.30 in Q2 2026.
- How has Kiniksa Pharmaceuticals International, plc's EPS (diluted) changed year-over-year?
- Kiniksa Pharmaceuticals International, plc's EPS (diluted) increased by 30.4% year-over-year, from $0.23 to $0.30.
- What is the long-term trend for Kiniksa Pharmaceuticals International, plc's EPS (diluted)?
- Over 4 years (2021 to 2025), Kiniksa Pharmaceuticals International, plc's EPS (diluted) has grown at a -24.4% compound annual growth rate (CAGR), from -$2.29 to $0.75.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Kiniksa Pharmaceuticals International, plc's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude